Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.56 |
| ▸ | AGT | P01019 | 1/20 | 0.49 |
| ▸ | NAE1 | Q13564 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498030 | 0.94 | AGTR1 (0.64) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL8112903 | 0.94 | AGTR2 (0.52) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL28915096 | 0.93 | AGTR2 (0.54) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL1653579 | 0.88 | AGTR2 (0.57) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL3429149 | 0.88 | AGTR1 (0.57) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL10108979 | 0.87 | AGTR1 (0.66) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL15478941 | 0.87 | AGTR2 (0.59) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL14573953 | 0.87 | AGTR2 (0.49) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL9594207 | 0.85 | AGTR1 (0.54) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL14573941 | 0.85 | AGTR2 (0.49) | AGTR2AGTR1CYP3A4ADORA3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2413911-B1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA D D NOVO MESTO (SI) | 2014-02-19 | — | — | EP | disclosed |
| US-20120029201-A1 | PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | ZUPANCIC SILVO (SI) | 2012-02-02 | — | — | US | disclosed |
| US-20120029201-A1 | PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | ZUPANCIC SILVO (SI) | 2012-02-02 | — | — | US | disclosed |
| EP-1945629-B1 | PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | KRKA D D NOVO MESTO (SI) | 2012-02-01 | — | — | EP | disclosed |
| US-7884212-B2 | deprotection of triphenylmethane(trityl)of 1-[[cyclohexyloxy) carbonyl]oxy]-ethyl-2-ethoxy-1-[[2'-(N-triphenyl-methyltetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (trityl candesartan cilexetil) in methanol and in the presence of ZnCl2 | ZUPANCIC SILVO | 2011-02-08 | — | — | US | disclosed |
| US-7884212-B2 | deprotection of triphenylmethane(trityl)of 1-[[cyclohexyloxy) carbonyl]oxy]-ethyl-2-ethoxy-1-[[2'-(N-triphenyl-methyltetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (trityl candesartan cilexetil) in methanol and in the presence of ZnCl2 | ZUPANCIC SILVO | 2011-02-08 | — | — | US | disclosed |
| WO-2010112222-A1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA, D.D., NOVO MESTO (SI) | 2010-10-07 | — | — | WO | disclosed |
| US-20100197933-A1 | Process for the Preparation of Candesartan Cilexetil | ZUPANCIC SILVO | 2010-08-05 | — | — | US | disclosed |
| US-20100197933-A1 | Process for the Preparation of Candesartan Cilexetil | ZUPANCIC SILVO | 2010-08-05 | — | — | US | disclosed |
| US-20090318706-A1 | Process for the Preparation of Candesartan Cilexetil | ZUPANCIC SILVO | 2009-12-24 | — | — | US | disclosed |
| US-20090318706-A1 | Process for the Preparation of Candesartan Cilexetil | ZUPANCIC SILVO | 2009-12-24 | — | — | US | disclosed |
| EP-1833801-B9 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2009-02-25 | — | — | EP | disclosed |
| EP-1833801-B1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007042161-A1 | PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | KRKA, D.D. NOVO MESTO (SI) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318706-A1 | Process for the Preparation of Candesartan Cilexetil | REN, AGTR1, AGT | AGTR2 6/4885AGTR1 2/4885CYP3A4 1091/4885 |
| US-20100197933-A1 | Process for the Preparation of Candesartan Cilexetil | REN, AGTR1, AGT | AGTR2 6/4885AGTR1 2/4885CYP3A4 1091/4885 |
| US-20120029201-A1 | PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | REN, AGTR1, AGT | AGTR2 6/4885AGTR1 2/4885CYP3A4 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.